Hedge fund manager targets Jazz in another IPR patent challenge


A US hedge fund manager and a company he created has taken aim at Jazz Pharmaceuticals in an inter partes review patent challenge, marking the third time he has challenged a company’s patents.

Inter partes review, Kyle Bass, Jazz Pharmaceuticals, Xyrem, non-practicing entities

More on this story

Hedge fund manager defends IPR petitions